Genentech, Inc.

Oncomed Pharmaceuticals, Inc.

Genetech, Inc.

University of Michigan

Other

Mereo Biopharma 5, Inc.

Genenetech, Inc.

Genentch, Inc.

Austin L Gurney

Audrey Goddard

William I Wood

Paul J Godowski

Victoria Smith

Colin K Watanabe

J Christopher Grimaldi

Luc Roland Desnoyers

Kevin P Baker

Daniel Tumas

Ellen Filvaroff

Margaret Ann Roy

Sherman Fong

Kenneth J Hillan

Napoleone Ferrara

Zemin Zhang

David Botstein

Timothy Andrew Stewart

Dan L Eaton

James Pan

Mary E Gerritsen

Wei-Qiang Gao

Timothy Charles Hoey

Avi J Ashkenazi

Aaron Sato

P Mickey Williams

Sanjeev Satyal

Nicholas F Paoni

Fumiko Takada Axelrod

Jian Chen

John A Lewicki

Ivar J Kljavin

Mary A Napier

Hanspeter Gerber

Christopher John Bond

Steven W Sherwood

Jean-Philippe F Stephan

Maureen H Beresini

Laura Deforge

Maureen Fitch Bruhns

Jennie Powell Mather

Jean Philippe Stephan

Edward Thein Htun Van Der Horst

Hanzhong Li

Christopher Grimaldi

Satyajit Sujit Kumar Mitra

Ming-Hong Xie

Frederic J De Sauvage

Thomas J Wu

Camellia W Adams

Menno Van Lookeren

Alexandra L L Lazetic

Wan-ching Yen

Yuan Ching Liu

Richard L Vandlen

Daniel G Yansura

Krista Maureen McCutcheon

Hilary Clark

Jane Louise Grogan

Cecile Chartier-Courtaud

Bernd Wranik

Daniel L Eaton

Ellen M Maruoka

Jessica S Foster

Maureen Fitch-Bruhns

Paul Polakis

Jo-Anne Hongo

Sophia S Kuo

Kenneth J Katschke, Jr

David A Lawrence

Menno VanLookeren

Arnon Rosenthal

Paul J Carter

David L Shelton

Diane Pennica

Michael F Clarke

Melanie Rose Mark

Ralph H Schwall

Wenjun Ouyang

Brian M Fendly

Robert L Cohen

Melissa A Starovasnik

Donna Marie Stone

Maximilien Murone

Kelly M Loyet

Sarah G Hymowitz

Arnold J Levine

Yan Wu

Andrew G Polson

Scott J Dylla

Kyung Jin Kim

Daniel Kirchhofer

James M Lee

Philip E Hass

Dorothy French

Weilan Ye

Gretchen Frantz

Sudeepta Aggarwal

Jakob Dupont

Robert Maurice Pitti

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.

VEGF/DLL4 binding agents and uses thereof

The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.

Combination therapy for treatment of disease

Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.

TIGIT-binding agents and uses thereof

Polypeptides and agents that bind a TNF receptor superfamily protein are disclosed, particularly agents that specifically bind GITR, OX40, or CD40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising GITRL, OX40L, or CD40L and/or bispecific agents. Also disclosed are methods of using the polypeptides or agents for inducing and/or enhancing the immune response, as well as methods for the treatment of diseases such as cancer.

Method of treating cancer by administering tumor necrosis factor receptor ligand superfamily (TNFRSF) single-chain polypeptides

Tight-binding agents and uses thereof

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.

Antibodies directed to IL-17A/IL-17F heterodimers

Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.

Method for making heteromultimeric molecules

Modified immunoglobulin molecules that specifically bind human VEGF and DLL4

The invention relates to novel polypeptides and cells comprising the polypeptides. The polypeptides and cells are used in methods to identify and/or isolate cells producing a protein with specific biological functions. In particular, the methods may be used for identifying, selecting, and isolating cells producing antigen-specific monoclonal antibodies.

Methods for identifying and isolating cells expressing a polypeptide

An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.

Compositions and methods for diagnosing and treating cancer

Binding agents that modulate the immune response are disclosed. The binding agents may include soluble receptors, polypeptides, and/or antibodies. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.

Immunotherapy with binding agents

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

Methods of treating cancer by administering a soluble receptor comprising a human Fc domain and the Fri domain from human frizzled receptor

Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agents

The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.

Compositions and methods for treating and diagnosing cancer

Growing community of inventors

Belmont, CA, United States of America

Austin L Gurney